These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31735133)

  • 1. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
    Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
    J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report.
    Ngo L; Miller E; Valen P; Gertner E
    J Med Case Rep; 2018 Feb; 12(1):48. PubMed ID: 29478412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome with Pembrolizumab for Lung Squamous Cell Carcinoma.
    Yoshida M; Hara S; Nishioka R; Kobayashi T; Murase Y; Kimura H; Mizushima I; Kawano M
    Intern Med; 2024 Jul; 63(14):2089-2096. PubMed ID: 38072406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remitting seronegative symmetrical synovitis with pitting edema syndrome complicated with primary lung cancer.
    Matsuoka H; Matsubara H; Sugimura A; Uchida T; Ichihara T; Miyauchi Y; Kondo T; Nakajima H
    Int Cancer Conf J; 2017 Jan; 6(1):16-21. PubMed ID: 31149462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome mimicking symptoms of polymyalgia rheumatica: a case report.
    Tarasiuk-Stanislawek K; Dumusc A; Favrat B; Kokkinakis I
    J Med Case Rep; 2022 Aug; 16(1):334. PubMed ID: 36028914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remitting seronegative symmetrical synovitis with pitting edema syndrome in maintenance hemodialysis.
    Matsugasumi T; Nakanouchi T; Mikami K; Shiraishi T; Kadoya M; Toriyama S; Taniguchi H; Fujihara A; Hongo F; Ukimura O
    IJU Case Rep; 2020 Nov; 3(6):278-281. PubMed ID: 33163925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remitting seronegative symmetrical synovitis with pitting edema: a case report.
    Tanaka Y; Kohchi K; Kitamoto K
    J Med Case Rep; 2022 Mar; 16(1):125. PubMed ID: 35331322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should Be Treated with Low-dose Prednisolone During Pembrolizumab Therapy.
    Yamamoto S; Fujita S; Mukai T; Sawachika H; Morita Y
    Intern Med; 2020 Feb; 59(4):597-598. PubMed ID: 31666471
    [No Abstract]   [Full Text] [Related]  

  • 9. Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should Be Treated with Low-dose Prednisolone During Pembrolizumab Therapy.
    Yamamoto S; Fujita S; Mukai T; Sawachika H; Morita Y
    Intern Med; 2020 Feb; 59(4):599. PubMed ID: 31666472
    [No Abstract]   [Full Text] [Related]  

  • 10. Idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome associated with bilateral pleural and pericardial effusions: a case report.
    Yanamoto S; Fukae J; Fukiyama Y; Fujioka S; Ouma S; Tsuboi Y
    J Med Case Rep; 2016 Jul; 10():198. PubMed ID: 27439425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
    Abdallah AO; Vallurupalli S; Kunthur A
    J Oncol Pharm Pract; 2016 Jun; 22(3):561-5. PubMed ID: 25956420
    [No Abstract]   [Full Text] [Related]  

  • 12. Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma.
    Yoshimura A; Yamanaka K; Tadokoro R; Wakita T; Fukae S; Yoshida T; Sekiguchi M; Kishikawa H
    IJU Case Rep; 2022 Jul; 5(4):219-222. PubMed ID: 35795121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer.
    Aoshima Y; Karayama M; Sagisaka S; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
    Intern Med; 2019 Nov; 58(22):3267-3271. PubMed ID: 31292397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An unusual case of remitting seronegative symmetrical synovitis with pitting edema: Case report and literature review.
    Joseph AD; Kumanan T; Aravinthan N; Suganthan N
    SAGE Open Med Case Rep; 2020; 8():2050313X20910920. PubMed ID: 32215210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab.
    Gauci ML; Baroudjian B; Laly P; Madelaine I; Da Meda L; Vercellino L; Bagot M; Lioté F; Pages C; Lebbé C
    Semin Arthritis Rheum; 2017 Oct; 47(2):281-287. PubMed ID: 28438383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.
    Zhong YY; McLean L; Buckle A; Siva S; Tran B
    Can J Urol; 2020 Aug; 27(4):10339-10341. PubMed ID: 32861263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remitting seronegative symmetrical synovitis with pitting edema syndrome postsecond COVID-19 vaccination: a case report.
    Hodifa Y; Khalayli N; Hodaifa A; Kudsi M
    Ann Med Surg (Lond); 2023 Aug; 85(8):4118-4120. PubMed ID: 37554915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
    Jeon SY; Lee NR; Yim CY
    BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome).
    Hung SC; Kung YY; Lin HY
    J Formos Med Assoc; 1999 Jul; 98(7):516-8. PubMed ID: 10463003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
    Tannir NM; Papadopoulos KP; Wong DJ; Aljumaily R; Hung A; Afable M; Kim JS; Ferry D; Drakaki A; Bendell J; Naing A
    Int J Cancer; 2021 Jul; 149(2):403-408. PubMed ID: 33709428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.